» Articles » PMID: 33964415

Predictors of Attrition in a Smoking Cessation Trial Conducted in the Lung Cancer Screening Setting

Abstract

Significance: Although it is a requirement that tobacco treatment is offered to cigarette smokers undergoing low-dose computed tomographic lung cancer screening (LCS), not all smokers engage in treatment. To understand the barriers to tobacco treatment in this setting, we evaluated predictors of attrition in a smoking cessation trial among individuals undergoing LCS.

Methods: Prior to LCS, 926 participants, 50-80 years old, completed the baseline (T0) phone assessment, including demographic, clinical, tobacco, and psychological characteristics. Following LCS and receipt of the results, participants completed the pre-randomization (T1) assessment.

Results: At the T1 assessment, 735 (79%) participants were retained and 191 (21%) dropped out. In multivariable analyses, attrition was higher among those who: smoked >1 pack per day (OR = 1.44, CI 1.01, 2.06) or had undergone their first (vs. annual) LCS scan (OR = 1.70, CI 1.20, 2.42). Attrition was lower among those with: more education (associates (OR = 0.67, CI = 0.46, 0.98) or bachelor's degree (OR = 0.56, CI 0.35, 0.91) vs. high school/GED), some (vs. none/a little) worry about lung cancer (OR = 0.60, CI 0.39, 0.92), or a screening result that was benign (OR = 0.57, CI 0.39, 0.82) or probably benign (OR = 0.38, CI 0.16, 0.90) vs. negative.

Conclusions: This study illuminated several LCS-related factors that contributed to trial attrition. Increasing tobacco treatment in this setting will require targeted strategies for those who report little lung cancer worry, are undergoing their first LCS exam, and/or who have a negative LCS result. Addressing attrition and reducing barriers to tobacco treatment will increase the likelihood of cessation, thereby reducing the risk of developing lung cancer.

Citing Articles

Association of individual and neighborhood socioeconomic status with outcomes of a smoking cessation intervention provided in the lung cancer screening setting.

Avila J, Flores E, Su Y, Haas J, Park E, Rigotti N Prev Med. 2024; 191:108207.

PMID: 39694102 PMC: 11776097. DOI: 10.1016/j.ypmed.2024.108207.


Lung Cancer Screening with Low-Dose CT: What We Have Learned in Two Decades of ITALUNG and What Is Yet to Be Addressed.

Mascalchi M, Picozzi G, Puliti D, Diciotti S, Deliperi A, Romei C Diagnostics (Basel). 2023; 13(13).

PMID: 37443590 PMC: 10340172. DOI: 10.3390/diagnostics13132197.


Attitudes towards the integration of smoking cessation into lung cancer screening in the United Kingdom: A qualitative study of individuals eligible to attend.

Groves S, McCutchan G, Quaife S, Murray R, Ostroff J, Brain K Health Expect. 2022; 25(4):1703-1716.

PMID: 35514094 PMC: 9327806. DOI: 10.1111/hex.13513.


Engaging Patients in Smoking Cessation Treatment within the Lung Cancer Screening Setting: Lessons Learned from an NCI SCALE Trial.

Williams R, Eyestone E, Smith L, Philips J, Whealan J, Webster M Curr Oncol. 2022; 29(4):2211-2224.

PMID: 35448154 PMC: 9027703. DOI: 10.3390/curroncol29040180.


Improved motivation and readiness to quit shortly after lung cancer screening: Evidence for a teachable moment.

Williams R, Cordon M, Eyestone E, Smith L, Luta G, McKee B Cancer. 2022; 128(10):1976-1986.

PMID: 35143041 PMC: 9038674. DOI: 10.1002/cncr.34133.

References
1.
Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

2.
Landy R, Young C, Skarzynski M, Cheung L, Berg C, Rivera M . Using Prediction Models to Reduce Persistent Racial and Ethnic Disparities in the Draft 2020 USPSTF Lung Cancer Screening Guidelines. J Natl Cancer Inst. 2021; 113(11):1590-1594. PMC: 8562965. DOI: 10.1093/jnci/djaa211. View

3.
Taylor K, Cox L, Zincke N, Mehta L, McGuire C, Gelmann E . Lung cancer screening as a teachable moment for smoking cessation. Lung Cancer. 2007; 56(1):125-34. DOI: 10.1016/j.lungcan.2006.11.015. View

4.
Heatherton T, Kozlowski L, Frecker R, Fagerstrom K . The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991; 86(9):1119-27. DOI: 10.1111/j.1360-0443.1991.tb01879.x. View

5.
Tammemagi M, Berg C, Riley T, Cunningham C, Taylor K . Impact of lung cancer screening results on smoking cessation. J Natl Cancer Inst. 2014; 106(6):dju084. PMC: 4081623. DOI: 10.1093/jnci/dju084. View